Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Temozolomide monotherapy Variant #13 | — | R 8 153 | 28d | 39.0 mo | — | 43 | R 350 573 PFS proxy | 1 |
Carboplatin and Vincristine Variant #02 | — | R 4 168 | 28d | — | — | — | — | — |
PCV Variant #01 Partial | — | R 389 | 42d | — | 159.6 mo | — | — | 1 |
Observation Partial | — | — | — | — | 93.6 mo | — | — | 1 |
Radiation therapy N/A - radiation Partial | — | — | 49d | 46.0 mo | — | 29 | — | 1 |
5 of 5 regimens shown